Treatment landscape

Finasteride: what the trials actually showed

It is the most-studied oral drug in the category. The data is genuinely good — and genuinely more modest than the marketing around it.

By the Editorial Team · Citations below · Medical review: pending — treat as education, not advice

Key points

Finasteride 1 mg is FDA-approved for male androgenetic alopecia; it works by inhibiting the conversion of testosterone to DHT.
In the pivotal 2-year trials, most treated men maintained or increased hair count versus progressive loss on placebo.
"Maintained" is doing a lot of work in that sentence: stopping further loss is the primary, best-supported effect.
Drug-related sexual adverse effects occurred in a small minority in trials; the long-tail debate about persistent effects is unresolved and worth discussing with a prescriber.

The mechanism, in one paragraph

Male pattern loss is androgen-driven: follicles in susceptible zones miniaturize under the influence of dihydrotestosterone (DHT). Finasteride inhibits 5-alpha-reductase type II, the enzyme that converts testosterone to DHT, lowering scalp and serum DHT substantially. Less DHT, slower miniaturization. That's the whole theory, and it's well-supported.

The pivotal evidence

The 1998 randomized, placebo-controlled trials (1,553 men aged 18–41 with mild-to-moderate vertex loss) found that at two years, treated men averaged a significant increase in hair count in the target area while the placebo group continued losing. Investigator and patient assessments aligned. Follow-on extension studies out to five years showed the gap between treated and untreated men widening over time — mostly because untreated loss keeps compounding.

Two honest caveats. First, enrollment skewed young with vertex-pattern loss; evidence in older men and purely frontal patterns is weaker. Second, average improvements are modest in cosmetic terms — the reliable win is keeping what you have.

The side-effect question, without spin

In the pivotal trials, drug-related sexual adverse events (decreased libido, erectile dysfunction, ejaculation disorder) were reported by roughly 4% of treated men versus about 2% on placebo, and most resolved on discontinuation — many even with continued use. Separately, a community of men report persistent symptoms after stopping ("post-finasteride syndrome"); the condition is contested in the literature, with case series and registry signals on one side and methodological critiques on the other. Our read: the trial-level risk numbers are small and real; the persistent-effects question is unresolved; both belong in a frank conversation with a prescriber — not in a comment-section verdict either way.

Practical evidence notes

Effect requires ongoing use; discontinuation returns you to your natural trajectory within about a year.
A 2017 systematic review and meta-analysis rated finasteride and minoxidil as the interventions with the strongest evidence in male androgenetic alopecia.
Topical finasteride formulations are an active research area aiming at similar efficacy with lower systemic exposure; quality of evidence is growing but thinner than for the oral form.

This article is education, not medical advice, and doesn't create a clinician-patient relationship. Finasteride is a prescription medicine with real risks and contraindications — decisions about it belong with you and a licensed clinician. We are independent: no pharmaceutical funding, nothing to sell you.

Citations

Kaufman KD, et al. Finasteride in the treatment of men with androgenetic alopecia. Finasteride Male Pattern Hair Loss Study Group. J Am Acad Dermatol. 1998;39(4 Pt 1):578-589.
The Finasteride Male Pattern Hair Loss Study Group. Long-term (5-year) multinational experience with finasteride 1 mg in the treatment of men with androgenetic alopecia. Eur J Dermatol. 2002;12(1):38-49.
Adil A, Godwin M. The effectiveness of treatments for androgenetic alopecia: a systematic review and meta-analysis. J Am Acad Dermatol. 2017;77(1):136-141.e5.